The FDA announced on Nov. 18, 2024, that Endo USA, Inc. is recalling Clonazepam Orally Disintegrating Tablets due to labeling errors regarding declared strength. The agency classified the Class I recall as voluntary.
How to tell if you have it
- Brand: Endo
- Product: Clonazepam Orally Disintegrating Tablets, USP, 0.125 mg, C-IV, Rx Only
- Quantity: 60 tablets per carton (10 blister cards)
- NDC#: 49884-306-02 (carton), NDC #: 49884-306-52 (blisters)
- Lot #: 550174101
- Expiration: 01/31/2027
- Distributed by: PAR Pharmaceutical, Chestnut Ridge, NY 10977
- Distribution: Nationwide in the USA
The hazard
The FDA stated that some cartons were incorrectly labeled regarding the declared strength of the drug. The agency noted that the blister strips inside the product carton reflect the correct strength.
Context
GovInfoNow's records show Endo USA, Inc. has issued four other recalls since Dec. 20, 2024, including a March 13, 2026, recall for Buprenorphine Injection due to crystallization risk and October 10, 2025, and September 5, 2025, recalls for Everolimus Tablets due to impurity risks. Other recent recalls of similar products include Inventia Chlorthalidone Recall (Sept. 3, 2026), Slate Run Recalls Eptifibatide Injection Due to Labeling Error (Feb. 12, 2026), and Inventia Healthcare Chlorthalidone Tablets Recall (June 5, 2026).